| dbo:abstract
|
- Axona was previously marketed as a medical food for the clinical dietary management of the impairment of metabolic processes associated with mild to moderate Alzheimer's disease. It is a proprietary formulation of fractionated palm kernel oil (caprylic triglyceride), a medium-chain triglyceride. Cericin, the company that makes Axona, states that during digestion, caprylic triglyceride is broken down into ketones, which provide an alternative energy source for the brain. Its use is based on the idea that the brain's ability to use its normal energy source, glucose, is impaired in Alzheimer's disease. Axona was first sold in March 2009. In 2013, FDA determined that Axona is misbranded under section 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(a)(1)] because the labeling is false and misleading in that the product is labeled and marketed as a medical food but does not meet the statutory definition of a medical food. Axona has not been approved by the US Food and Drug Administration (FDA) as a drug to treat Alzheimer's and the efficacy of managing the health of Alzheimer's patients by use of this medical food has been questioned by experts in the field, including the Alzheimer's Association. (en)
- Trioctanoato de glicerol, é o composto orgânico, éster triglicerídeo do ácido caprílico de fórmula C27H50O6, comercializado nos EUA como Axona é um comercializado para o manejo clínico da dieta da perda de valor dos processos metabólicos associados com doença de Alzheimer leve a moderada. (pt)
|
| dbo:alternativeName
|
- Glycerol trioctanoate; Tricaprylin (en)
|
| dbo:iupacName
|
- Propane-1,2,3-triyl tri(octanoate) (en)
- [2-octanoyloxy-1-(octanoyloxymethyl)ethyl]octanoate (en)
|
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 13640 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:date
| |
| dbp:imagefile
|
- Caprylic triglyceride.svg (en)
- Caprylidene-3D-balls.png (en)
|
| dbp:imagesize
|
- 260 (xsd:integer)
- 270 (xsd:integer)
|
| dbp:othernames
|
- Glycerol trioctanoate; Tricaprylin (en)
|
| dbp:pin
|
- Propane-1,2,3-triyl tri (en)
|
| dbp:reason
|
- Article focuses too much on "medical food" aspects rather than natural occurrence, physical/chemical properties, normal biochemical role, etc. (en)
|
| dbp:systematicname
|
- [2-octanoyloxy-1-ethyl] octanoate (en)
|
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Trioctanoato de glicerol, é o composto orgânico, éster triglicerídeo do ácido caprílico de fórmula C27H50O6, comercializado nos EUA como Axona é um comercializado para o manejo clínico da dieta da perda de valor dos processos metabólicos associados com doença de Alzheimer leve a moderada. (pt)
- Axona was previously marketed as a medical food for the clinical dietary management of the impairment of metabolic processes associated with mild to moderate Alzheimer's disease. It is a proprietary formulation of fractionated palm kernel oil (caprylic triglyceride), a medium-chain triglyceride. Cericin, the company that makes Axona, states that during digestion, caprylic triglyceride is broken down into ketones, which provide an alternative energy source for the brain. Its use is based on the idea that the brain's ability to use its normal energy source, glucose, is impaired in Alzheimer's disease. Axona was first sold in March 2009. (en)
|
| rdfs:label
|
- Axona (en)
- Trioctanoato de glicerol (pt)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
